Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma
N/A
50 Years
Both
Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin
Trial Information
Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma
To determine the disease free survival and overall survival of patients with ALL and ANLL
after induction failure, in relapse, or subsequent remission from CML in several phases or
recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and
cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling
donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide
(CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia
or High Grade Lymphoma
Inclusion Criteria:
HLA identical donor- adequate organ function
- other life threatening disease
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
overall survival
Outcome Time Frame:
october 2009
Safety Issue:
No
Principal Investigator
Robert Lowsky
Investigator Role:
Principal Investigator
Investigator Affiliation:
Stanford University
Authority:
United States: Institutional Review Board
Study ID:
BMT34
NCT ID:
NCT00186290
Start Date:
December 1989
Completion Date:
October 2009
Related Keywords:
- Lymphoma, Non-Hodgkin
- Leukemia
- Blood and Marrow Transplant (BMT)
- Lymphomas: Non-Hodgkin
- Leukemia
- Lymphoma
- Lymphoma, Non-Hodgkin
Name | Location |
|---|---|
| Stanford University School of Medicine | Stanford, California 94305-5317 |
